Aspirin/omeprazole 100/40

Drug Profile

Aspirin/omeprazole 100/40

Alternative Names: Acetylsalicyclic acid/omeprazole 100/40; Omeprazole/acetylsalicyclic acid 40/100; Omeprazole/aspirin 40/100; PA-10040

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator POZEN
  • Developer Aralez Pharmaceuticals Inc.
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiplatelets; Antipyretics; Antirheumatics; Antiulcers; Benzimidazoles; Gastric antisecretories; Non-opioid analgesics; Salicylates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration NSAID-induced ulcer
  • Phase I Cardiovascular disorders

Most Recent Events

  • 09 Jan 2017 Preregistration for NSAID-induced ulcer (Prevention) in European Union (PO)
  • 09 Jan 2017 Aralez Pharmaceuticals announces submission of MAA to the EMA
  • 06 Aug 2013 Phase-I clinical trials in NSAID-induced ulcer (prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top